🇺🇸 FDA
Pipeline program

MEDI8897

D5290C00003

Phase 2 small_molecule completed

Quick answer

MEDI8897 for Respiratory Syncytial Virus Infections is a Phase 2 program (small_molecule) at MedImmune with 1 ClinicalTrials.gov record(s).

Program details

Company
MedImmune
Indication
Respiratory Syncytial Virus Infections
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials